Infliximab (Remicade) Pharmacokinetic ELISA
Infliximab (Remicade®) is a chimeric monoclonal antibody against tumour necrosis factor alpha (TNF- α). Infliximab neutralizes the biological activity of TNF- α by binding with high affinity to the soluble (free floating in the blood) and transmembrane (located on the outer membranes of T cells and similar immune cells) forms of TNF-α, and inhibits or prevents the effective binding of TNF-α with its receptors. The Infliximab ELISA kit is designed to measure free Infliximab with high specificity and sensitivity . This assay employs the sandwich enzyme immunoassay technique. A precoated anti-Infliximab 96 well plate is provided. Calibrator, quality control samples and test samples are pipetted into the appropriate wells. Infliximab present in biological matrices is bound by the immobilized capture antibody. After washing away any unbound substances, enzyme linked detection antibody is added to the wells. The plate is washed to remove any unbound antibody-enzyme reagent and a substrate solution is added to the wells for color development. The color development is proportional to the amount of Infliximab present in test samples and the concentration is calculated from the standard series.
Număr Catalog 1061-EL-1611-091CategorieAfaceri și industrie > Știință și laboratorFurnizorAffinitylmmunoGentaurDimensiune1X96 wellsTipsingle